Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Parallel Trial of Famitinib Malate at Different Doses Combined With Camrelizumab for the Treatment of Recurrent and Metastatic Cervical Cancer

NCT07143292 is registered in ClinicalTrials.gov with Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University as lead sponsor.

NCT NCT07143292
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07143292 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Parallel Trial of Famitinib Malate at Different Doses Combined With Camrelizumab for the Treatment of Recurrent and Metastatic Cervical Cancer
Lead sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 30, 2025
Completion date
June 30, 2028
Enrollment
120 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer metastatic, cervical cancer recurrent